Hexedrone - PsychonautWiki
Open main menu
Not to be confused with N-Ethylhexedrone (Hexen).
Summary sheet: Hexedrone
Hexedrone
Hexedrone.svg
Chemical Nomenclature
Common names Hexedrone
Systematic name 2-(methylamino)-1-phenylhexan-1-one
Class Membership
Psychoactive class Stimulant
Chemical class Cathinone
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 30 mg
Light 50 - 70 mg
Common 70 - 100 mg
Strong 100 - 125 mg
Heavy 125 mg +
Duration
Total 1 - 4 hours
Onset 15 - 30 minutes
After effects 1 - 12 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

Hexedrone is a novel synthetic stimulant of the cathinone class. It has been speculated to act as a norepinephrine-dopamine-reuptake-inhibitor (NDRI).

Subjective effects include stimulation, disinhibition, thought acceleration and euphoria.

Little is known about toxicity, addiction, and abuse potential of hexedrone. Due to its novelty and extremely short history of human usage, all information related to the use of this compound should be treated with caution.

Contents

Chemistry

Hexedrone is a cathinone, which is closely related to amphetamines, but have a ß-substituted ketone group as well. Relative to regular cathinone, which can be found in the Khat plant, hexedrone consists of two added substitutions. At the R2 position, a n-Butyl substitution forms a hexan chain. The second substitution is a Methyl group, that's attached to the amine (R4), thus forming N-Methyl.

Pharmacology

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other cathinones such as pentedrone and others. Hexedrone most likely acts as both a dopamine and norepinephrine reuptake inhibitor. This allows dopamine and norepinephrine to build up within the brain, resulting in stimulating and euphoric effects.

The decreased potency, compared to both pentedrone as well as ethyl-hexedrone can be easily explained. Compared to pentedrone, there is a larger non-polar side chain. Ethyl-hexedrone has an ethyl group, instead of a methyl, which results in a significantly shifted electronegativity.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses are more likely to induce the full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.

Physical effects
 

After effects
 


Toxicity and harm potential

Since hexedrone has been insufficiently studied and most data consists of speculation and user experiences, one should be especially cautious when it comes to the risks and harm this substance may pose, especially in terms of seriouslong-term health hazards.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of Hexedrone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of hexedrone develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Hexedrone presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of Hexedrone all stimulants will have a reduced effect.

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Brazil: On September 7, 2018, all Cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.[1]
  • Germany: Hexedrone is controlled under the NpSG (New Psychoactive Substances Act)[2] as of November 26, 2016.[3] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[4]
  • Switzerland: Hexedrone can be considered a controlled substance as a defined derivative of Cathinone under Verzeichnis E point 1. It is legal when used for scientific or industrial use.[5]
  • United Kingdom: Hexedrone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.[6]

See also

External links

References

 

This article does not cite enough references.

You can help by adding some.

  1. New blanket ban on synthetic illegal drugs is approved (Portuguese) | http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/combate-a-drogas-ilicitas-sinteticas-fica-mais-facil
  2. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019. 
  3. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 23, 2019. 
  4. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019. 
  5. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  6. United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made